{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:36:47Z","timestamp":1777383407376,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,8,18]],"date-time":"2010-08-18T00:00:00Z","timestamp":1282089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s00417-010-1440-8","type":"journal-article","created":{"date-parts":[[2010,8,17]],"date-time":"2010-08-17T10:12:36Z","timestamp":1282039956000},"page":"193-200","source":"Crossref","is-referenced-by-count":27,"title":["Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3\u00a0months (Report 1)"],"prefix":"10.1007","volume":"249","author":[{"given":"Siamak","family":"Moradian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hooshang","family":"Faghihi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babak","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niloofar","family":"Piri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Ahmadieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Soheilian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hossein","family":"Dehghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Azarmina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Riazi","family":"Esfahani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,18]]},"reference":[{"key":"1440_CR1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","volume":"98","author":"The Branch Vein Occlusion Study Group","year":"1984","unstructured":"The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271\u2013282","journal-title":"Am J Ophthalmol"},{"key":"1440_CR2","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/archopht.1996.01100140443012","volume":"114","author":"P Mitchell","year":"1996","unstructured":"Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114:1243\u20131247","journal-title":"Arch Ophthalmol"},{"key":"1440_CR3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2006.06.061","volume":"114","author":"S Cugati","year":"2007","unstructured":"Cugati S, Wang JJ, Knudtson MD, Rochtchina E, Klein BE, Wong TY, Mitchell P (2007) Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 114:520\u2013524","journal-title":"Ophthalmology"},{"key":"1440_CR4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1442-9071.1980.tb00340.x","volume":"8","author":"DV Greer","year":"1980","unstructured":"Greer DV, Constable IJ, Cooper RL (1980) Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 8:207\u2013209","journal-title":"Aust J Ophthalmol"},{"key":"1440_CR5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/s-2008-1035245","volume":"208","author":"C Kalogeropoulos","year":"1996","unstructured":"Kalogeropoulos C, Donati G, Pizzolato GP, Pournaras CJ (1996) Morphology of early retinal lesions after experimental venous occlusion. Klin Monatsbl Augenheilkd 208:375\u2013376","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1440_CR6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1034\/j.1600-0420.2000.078002187.x","volume":"78","author":"J Larsson","year":"2000","unstructured":"Larsson J, Bauer B, Andreasson S (2000) The 30-Hz flicker cone ERG for monitoring the early course of central retinal vein occlusion. Acta Ophthalmol Scand 78:187\u2013190","journal-title":"Acta Ophthalmol Scand"},{"key":"1440_CR7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-2008-1045665","volume":"203","author":"GE Lang","year":"1993","unstructured":"Lang GE, Handel A (1993) Results of laser coagulation of branch retinal vein occlusions. Klin Monatsbl Augenheilkd 203:180\u2013188","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"1440_CR8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ajo.2004.11.011","volume":"139","author":"E Esrick","year":"2005","unstructured":"Esrick E, Subramanian ML, Heir JS, Ak D, Topping TM, Frederick AR, Morley MG (2005) Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 139:653\u2013657","journal-title":"Am J Ophthalmol"},{"key":"1440_CR9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/00006982-200510000-00006","volume":"7","author":"O Cekic","year":"2005","unstructured":"Cekic O, Chang S, Tseng JJ, Barile GR, Del Priore LV, Weissman H, Schiff WM, Ober MD (2005) Intravitreal triamcinolone injection for treatment for macular edema secondary to branch retinal vein occlusion. Retina 7:851\u2013855","journal-title":"Retina"},{"key":"1440_CR10","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1600-0420.2005.00490.x","volume":"83","author":"K Krepler","year":"2005","unstructured":"Krepler K, Ergun E, Sacu S, Richter-Muksch S, Wagner J, Stur M, Wedrich A (2005) Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot study. Acta Ophthalmol Scand 83:600\u2013604","journal-title":"Acta Ophthalmol Scand"},{"issue":"12","key":"1440_CR11","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00417-006-0348-9","volume":"244","author":"A Ramezani","year":"2006","unstructured":"Ramezani A, Entezari M, Moradian S, Tabatabaei H, Kadkhodaei S (2006) Intravitreal triamcinolone for acute central retinal vein occlusion; a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 244(12):1601\u20131606","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1440_CR12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ajo.2005.12.011","volume":"141","author":"SD Chen","year":"2006","unstructured":"Chen SD, Sundaram V, Lochhead J, Patel CK (2006) Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 141:876\u2013883","journal-title":"Am J Ophthalmol"},{"key":"1440_CR13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.eye.6701803","volume":"20","author":"A Ozkiris","year":"2006","unstructured":"Ozkiris A, Evereklioglu C, Erkilic K, Dogan H (2006) Intravitreal triamcinolone acetonide for treatment of persistent macular edema in branch retinal vein occlusion. Eye 20:13\u201317","journal-title":"Eye"},{"issue":"2","key":"1440_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00347-003-0975-z","volume":"101","author":"GB Jaissle","year":"2004","unstructured":"Jaissle GB, Szurman P, Bartz-Schmidt KU (2004) Ocular side effects and complications of intravitreal triamcinolone acetonide injection. Ophthalmology 101(2):121\u2013128","journal-title":"Ophthalmology"},{"key":"1440_CR15","first-page":"758","volume":"137","author":"S Kaushik","year":"2004","unstructured":"Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R (2004) Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 137:758\u2013760","journal-title":"Am J Ophthalmol"},{"key":"1440_CR16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ajo.2005.11.050","volume":"141","author":"JT Thompson","year":"2006","unstructured":"Thompson JT (2006) Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 141:629\u2013637","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"1440_CR17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","volume":"127","author":"IU Scott","year":"2009","unstructured":"Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M, SCORE Study Research Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127(9):1115\u20131128","journal-title":"Arch Ophthalmol"},{"key":"1440_CR18","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(98)93020-2","volume":"105","author":"J Pe'er","year":"1998","unstructured":"Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105:412\u2013416","journal-title":"Ophthalmology"},{"key":"1440_CR19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archopht.120.12.1644","volume":"120","author":"SR Boyd","year":"2002","unstructured":"Boyd SR, Zachary I, Chakravarthy U, Gj A, Wisdom GB, Cree IA, Martin JF, Hykin PG (2002) Correlation of increased vascular endothelial growth factor with neovascularization and permeability. Arch Ophthalmol 120:1644\u20131645","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1440_CR20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1167\/iovs.08-2510","volume":"50","author":"M Funk","year":"2009","unstructured":"Funk M, Kriechbaum K, Prager F, Benesch T, Georgopoulos M, Zlabinger GJ, Schmidt-Erfurth U (2009) Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 50(3):1025\u20131032","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1440_CR21","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Jampel HD, Shah ST, Pasquale LR (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480\u20131487","journal-title":"N Engl J Med"},{"key":"1440_CR22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","volume":"27","author":"MD Rabena","year":"2007","unstructured":"Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419\u2013425","journal-title":"Retina"},{"key":"1440_CR23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3928\/1542-8877-20050701-15","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336\u2013339","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"4","key":"1440_CR24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/bjo.2007.127282","volume":"92","author":"K Kriechbaum","year":"2007","unstructured":"Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenaver W (2007) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92(4):518\u2013522","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"1440_CR25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00347-006-1355-2","volume":"103","author":"GB Jaissle","year":"2006","unstructured":"Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, V\u00f6lker M, Holz FG, Bartz-Schmidt KU (2006) Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 103(6):471\u2013475","journal-title":"Ophthalmologe"},{"key":"1440_CR26","unstructured":"Avastin (Product monograph 2005) Gardiner- Caldwell Communications Mississauga\u060c Ontario: Hoffmann-La Roche Ltd."},{"key":"1440_CR27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391\u2013400","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1440_CR28","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00417-008-0866-8","volume":"246","author":"EJ Chung","year":"2008","unstructured":"Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246(9):1241\u20131247","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1440_CR29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ajo.2006.12.037","volume":"143","author":"SA Pai","year":"2007","unstructured":"Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical anatomic and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601\u2013606","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"1440_CR30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ophtha.2008.10.017","volume":"116","author":"IU Scott","year":"2009","unstructured":"Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M (2009) SCORE Study Investigator Group SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology Mar 116(3):504\u2013512","journal-title":"Ophthalmology Mar"},{"key":"1440_CR31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000183844","volume":"223","author":"F Rench","year":"2009","unstructured":"Rench F, Jonas JB, Spandau UHM (2009) Early intravitreal bevacizumab for non-ischemic branch retinal vein occlusion. Ophthalmologica 223:124\u2013127","journal-title":"Ophthalmologica"},{"key":"1440_CR32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00417-008-0916-2","volume":"247","author":"GB Jaissle","year":"2009","unstructured":"Jaissle GB, Leitritz M, Gelisken F, Bartz ZF, KU SSP (2009) One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:27\u201333","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"1440_CR33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/IAE.0b013e31804a7af2","volume":"27","author":"Y Matsumota","year":"2007","unstructured":"Matsumota Y, Freund KB, Peirettie E, Cooney MJ (2007) Rebound macular edema following bevacizumab (Avastin) therapy for venous occlusion disease. Retina 27(4):426\u2013431","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1440-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-010-1440-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-010-1440-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:11:21Z","timestamp":1559437881000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-010-1440-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,18]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["1440"],"URL":"https:\/\/doi.org\/10.1007\/s00417-010-1440-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,18]]}}}